Replimune gains as FDA to discuss path for rejected skin cancer drug
Source: SeekingAlpha
2025-09-02 15:00:47 ET
More on Replimune Group
- Replimune Group: The Prospects For FDA Approval After Rejection
- Replimune: A Surprise CRL Exposes Fragility Of The Melanoma Program
- Biotech sector slips amid reported return of ousted FDA official
- Biggest stock movers Monday: BLDE, COMM, SPOT, ON, and more
- Seeking Alpha’s Quant Rating on Replimune Group
Read the full article on Seeking Alpha
For further details see:
Replimune gains as FDA to discuss path for rejected skin cancer drug
Replimune Group Inc.
NASDAQ: REPL
REPL Trading
-10.42% G/L:
$4.6493 Last:
4,448,331 Volume:
$5.06 Open:
REPL Latest News
REPL Stock Data
$646,543,607
51,607,887
0.33%
61
N/A
Biotechnology & Life Sciences
Healthcare
US
Woburn
